GeneriCo is focused on developing and marketing niche generic pharmaceuticals that have been neglected by mid and large generic companies and also have an embedded drug delivery technology. The combination of neglected, technically challenging formulation, and economic size makes the GeneriCo pipeline not appealing to middle and large competitors, and too complex for tightly focused small generic companies.
Funding Rounds (3) - $4.19MUpdate
Current Team (1)Update
|Aug 10, 2015||WSJ Blogs - The Daily Startup: Editas Medicine Raises $120M for Gene-Editing Drugs|
|Jul 1, 2015||Boston Tech Flash - http://www.bizjournals.com/stlouis/blog/biznext/2015/07/generic-drug-startup-raises-3-6-million.html|
|Mar 1, 2015||SEC - SEC FORM D|
|May 24, 2013||SEC - SEC FORM D|
4041 FOREST PARK AVE.
St Louis, MO 63108